cytarabine has been researched along with melflufen in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chhabra, J; Kumar, R; Narang, R; Pahwa, R | 1 |
| Gullbo, J; Haglund, C; Hassan, SB; Höglund, M; Larsson, R; Strese, S; Velander, E | 1 |
1 review(s) available for cytarabine and melflufen
| Article | Year |
|---|---|
Melphalan: Recent insights on synthetic, analytical and medicinal aspects.
Topics: Antineoplastic Agents, Alkylating; Drug Resistance, Neoplasm; Humans; Melphalan; Multiple Myeloma; Prodrugs; Structure-Activity Relationship | 2022 |
1 other study(ies) available for cytarabine and melflufen
| Article | Year |
|---|---|
In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia.
Topics: Animals; Antigens, CD34; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Synergism; Female; HL-60 Cells; Humans; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Male; Melphalan; Mice, SCID; Middle Aged; Neoplastic Stem Cells; Phenylalanine; Time Factors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2017 |